 |
|
|
| |
Pharmacokinetics, Safety and Tolerability of EDP-239, a Novel Hepatitis C (HCV) NS5A inhibitor, in Patients with HCV Infection
|
| |
| |
Reported by Jules Levin
ICAAC 2015 Sept 17-21 San Diego, CA
Lijuan Jiang1, Xuemin Jiang2, Kiran Dole2, Eric Lawitz3, Fred Poordad3, Stefan Zeuzem4, Kimberly Caliri1, Kenneth Tack1, Richard Colvin2, Yat Sun Or1
1Enanta Pharmaceuticals Inc., Watertown MA; 2Novartis Institutes for Biomedical Research, Cambridge MA; 3The Texas Liver Institute, San Antonio TX; 4Goethe University Hospital, Frankfurt, Germany
|
| |
|
|
|
|
|
